TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06709040

Intervention type: DRUG
Intervention: Somapacitan
Description: Participants will be treated with commercially available somapacitan according to routine clinical practice at the discretion of the treating physician.
Study: NCT06708481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P11-4, a self-assembling peptide
Description: rationally designed peptide, the monomers of which self-assemble into a biocompatible fibrillar scaffold that mimics the enamel matrix in response to particular environmental cues

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P11-4, a self-assembling peptide with flouride
Description: self assembling peptide with 500 ppm sodium fluoride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: resin infilteration
Description: Improvement of white spot lesions appearance by infiltration occurs due to a change in the refractive index since the refractive index of enamel (1.62-1.65) is different than that of air (1.00). Infiltration of the lesions with an infiltrate that has a refractive index of 1.52 is able to mask the lesion
Study: NCT06706804

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wipe Bathing
Description: In groups of 2-3 pregnant women in this group, the researcher will explain the stages of newborn wiping bath application on the newborn model, and then the pregnant women will individually apply the bath on the model. The trainings will be held in the pregnant school at the appropriate times, or in an empty room determined by the hospital administration if there is another planned training in the pregnant school. In the wiping bath training, women will be provided to perform the procedure on the model appropriate to the gender of their babies for genital area cleaning based on the gender of newborns. After the training, pregnant women will be given a home follow-up form to record the first bath time of their babies after birth, the umbilical cord fall time and the body temperature of their babies (before bathing, immediately after bathing and 10 minutes after bathing) and will be told how to fill it out.
Study: NCT06708286

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus, Reduced Diphtheria and Acellular Pertussis (Five Components) Combined Vaccine, Adsorbed (Tdcp))
Description: 1 dose of Tdcp vaccine (0.5ml) on day 0

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 23-valent Pneumococcal Polysaccharide Vaccine (PPV23)
Description: 1 dose of PPV23 vaccine (0.5ml) on day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tdcp
Description: 1 dose of Tdcp vaccine (0.5ml) on day 0

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPV23
Description: 1 dose of PPV23 vaccine (0.5ml) on day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tdcp
Description: 1 dose of Tdcp vaccine (0.5ml) on day 0

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPV23
Description: 1 dose of PPV23 vaccine (0.5ml) on day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tdcp
Description: 1 dose of Tdcp vaccine (0.5ml) on day 0

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPV23
Description: 1 dose of PPV23 vaccine (0.5ml) on day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tdcp
Description: 1 dose of Tdcp vaccine (0.5ml) on day 0

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Diphtheria-tetanus-acellular pertussis vaccine (DTaP)
Description: 1 dose of DTaP vaccine (0.5ml) on day 0
Study: NCT06710717

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 CAR-T cells
Description: Study participant will be given single infusion of autologous CD19 CAR-T cells following lymphodepletion chemotherapy
Study: NCT06709417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab 200mg iv Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Liposomal paclitaxel: 150mg/m2, Q3W + cisplatin: 75mg/m2, Q3W (combined with PD-1 therapy) Liposomal paclitaxel: 50mg/m2, Q3W + cisplatin: 20mg/m2, Q3W (combined with radiotherapy )

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: The total dose is 5040cCy in 28 fractions (5 days per week, 1.8 Gy/day).
Study: NCT06710756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [203Pb]Pb-PSV359
Description: \[203Pb\]Pb-PSV359 is administered by intravenous bolus injection for single-photon emission computed tomography imaging.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [203Pb]Pb-PSV359
Description: \[203Pb\]Pb-PSV359 is administered by intravenous bolus injection for single-photon emission computed tomography imaging.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [212Pb]Pb-PSV359
Description: \[212Pb\]Pb-PSV359 is administered by intravenous infusion for treatment of FAP expressing cancers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [212Pb]Pb-PSV359
Description: \[212Pb\]Pb-PSV359 is administered by intravenous infusion for treatment of FAP expressing cancers.
Study: NCT06709469

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous CD19/CD22 CAR T cells
Description: A total of two doses of autologous CD19/CD22 CAR T cells (first dose of up to 0.75x106/kg fresh cells), and a second infusion of unfrozen cells (same dose) if there has been no ≥ grade 1 cytokine-release syndrome (CRS) in the next 72 h; intravenously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic CART-NKG2D cells
Description: A total of up to 3x106/kg allogeneic CART-NKG2D cells divided in three doses of up to 1x106/kg will be infused; intravenously. First infusion of fresh cells, and the 2nd and 3rd infusion of unfrozen cells (same dose) if there has been no ≥ grade 1 CRS (every 48 hours).
Study: NCT06708000

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Clinical Likelihood (CL) Model-Based Diagnostic Strategy
Description: The Clinical Likelihood (CL) model-based diagnostic strategy utilizes two models: the RF-CL model and the CACS-CL model. These models assess the pre-test probability of obstructive coronary artery disease (CAD) based on patient factors such as age, sex, symptoms, and traditional cardiovascular risk factors like smoking, diabetes, and hypertension. The CACS-CL model incorporates coronary artery calcium scoring to further refine the risk assessment. Patients identified with a low likelihood of CAD may avoid unnecessary diagnostic testing, such as cardiac CT, while maintaining diagnostic accuracy and safety. This approach aims to optimize resource use, reduce patient burden, and focus on other potential causes of symptoms when CAD is unlikely.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care treatment
Description: Patients will follow the standard diagnostic pathway, which includes the use of cardiac CT and other advanced diagnostic procedures based on clinical guidelines. This approach is the current standard of care for patients with suspected obstructive coronary artery disease (CAD). The control group allows for comparison of outcomes with those in the intervention arm, particularly in terms of resource utilization, patient safety, and diagnostic accuracy.
Study: NCT06708455

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RAPA-201 Rapamycin Resistant T Cells
Description: Autologous Rapamycin-Resistant Th1/Tc1 Cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy Prior to RAPA-201 Therapy
Description: Carboplatin + Paclitaxel Regimen (CP Regimen)
Study: NCT06709027

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention Group (Mobile Health Management Intervention)
Description: Participants in this group will receive a mobile health management intervention over a period of 12 weeks. This intervention includes the use of a mobile application designed for health management, psychological support, and monitoring,et al， with the aim of improving the mental health status of elderly patients with depression.
Study: NCT06710418

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activity Tracking
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activity Tracking
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cognitive Assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cognitive Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Packed Red Blood Cell Transfusion
Description: Undergo PRBC transfusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Packed Red Blood Cell Transfusion
Description: Undergo PRBC transfusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT06706856

Intervention type: DIAGNOSTIC_TEST
Intervention: MR exam
Description: Participants will undergo an advanced magnetic resonance (MR) examination of the abdomen and liver.

Intervention type: DIAGNOSTIC_TEST
Intervention: US exam
Description: Participants will undergo an abdominal ultrasound (US) examination using a full-size US system. Some participants may undergo a point-of-care abdominal US exam with a handheld US system, if possible.

Intervention type: OTHER
Intervention: Blood draw
Description: Participants will undergo a blood draw of approximately 25 mL volume.

Intervention type: OTHER
Intervention: Physical measurements
Description: Participants will have their height, weight and waist circumference measured. Vital signs including respiratory frequency, heart rate, temperature, and blood pressure will be measured.

Intervention type: OTHER
Intervention: Questionnaires
Description: Participants will be asked to fill out questionnaires to collect information about their prescribed medications, demographics, medical and surgical histories, prior laboratory results, physical activity and lifestyle measures, and potential alcohol intake (AUDIT questionnaire).
Study: NCT06709703

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Kinematic aligned total knee replacement
Description: Replacement of worn knee cartilage using a prosthesis. The alignment is determined according to the patient's anatomy and ligament balance.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kinematic aligned total knee replacement
Description: Replacement of worn knee cartilage using a prosthesis. The alignment is determined according to the patient's anatomy and ligament balance.
Study: NCT06707532

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Induction of anaesthesia:~* Fentanyl 1-3ug/kg/m.c i.v.~* Ketamine 50mg i.v.~* Propofol 1.5-2mg/kg/m.c i.v.~* Rocuronium 5mg (b.w.\<60kg) 10mg (b.w.\>60kg) i.v. Precurarisation~* Chlorucinylcholine 1-1.5mg/kg/m.c i.v. -\> Intubation~Application (cycle of 5 pulses with 2000V biphasic alternating current) - during PFA:~- In case of ventilatory distress pPeak \>30 cm H2O ad hoc Propofol 0.25-0.75mg/kg/m.c i.v.~Elimination of neuromuscular blockade:~- To exclude residual relaxation after pre-curative: 1mg Atropine i.v. + 0.5mg Neostigmine i.v.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: Induction of anaesthesia:~* Fentanyl 1-3ug/kg/m.c i.v.~* Ketamine 50mg i.v.~* Propofol 1.5-2mg/kg/m.c i.v.~* Rocuronium 5mg (b.w.\<60kg) 10mg (b.w.\>60kg) i.v. Precurarisation~* Chlorucinylcholine 1-1.5mg/kg/m.c i.v. -\> Intubation~Application (cycle of 5 pulses with 2000V biphasic alternating current) - during PFA:~- rocuronium 0.1-0.3mg/kg/m.c i.v. For TOF \<2~Abolition of neuromuscular blockade:~- Atropine 1-1.5mg i.v. + 1-3mg Neostigmine i.v. Or Sugammadex 2-4mg/kg/m.c i.v.
Study: NCT06707350

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Description: 8 cycles of 5-minute inflation and 5-minute deflation on 2 upper and lower limbs with a blood pressure cuff

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham condition (control group)
Description: 8 cycles of 5-minute inflation to a pressure of 20 mm Hg followed by 5-minute cuff deflation.
Study: NCT06707103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR987 0.1% gel
Description: 6mg topical gel for application plus Standard of Care (wound cleansing/dressings and compression bandaging)

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: Standard of Care (wound cleansing/dressings and compression bandaging)
Study: NCT06710184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin bolus of 300 mg followed by 75 mg daily until CAG

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin bolus of 300 mg followed by 75 mg daily until CAG

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fondaparinux Sodium
Description: Fondaprinux 2.5 mg subcutaneus daily until CAG (1.5 mg for patients with eGFR 20-50 ml/min/1.73m2)
Study: NCT06706921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Fluciclovine PET/CT Scan
Description: In this prospective study, an 18F-Fluciclovine PET/CT will be additionally obtained at baseline (pre-LuPSMA RLT), and after the 2nd, 4th, 6th LuPSMA RLT cycles.18F-Fluciclovine PET/CT will be acquired within 7 days from the PSMA PET.
Study: NCT06709183

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention-Control
Description: Nurses in this group will start the first oral care practice by using the oral care retractor on the model. Before starting the procedure, the nurses will fill in the 'Beck Mouth Assessment Guide' and after the procedure, they will fill in the 'Oral Care Practices Evaluation Form'. A rest period of at least 10 minutes will be provided before the second oral care application. Standard oral care will be applied during the second application. Similarly, nurses will complete the 'Beck Oral Assessment Guide' before the procedure and the 'Oral Care Practices Assessment Form' after the procedure. At the end of both procedures, nurses will complete the 'Quebec Assistive Technology User Satisfaction Assessment Questionnaire (Q-ATUSA)' and the 'Interview Form'. The 'Interview Form' will be used to collect nurses' experiences and opinions about the oral care procedure. During the interview, audio recordings will be made with the knowledge of the nurses.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control - intervention
Description: In the first oral care procedure, nurses in this group will perform standard oral care on the model without using the oral care retractor. They will complete the 'Beck Oral Assessment Guide' before the procedure and the 'Oral Care Practices Evaluation Form' after the procedure. There will be a rest period of at least 10 minutes before the second oral care procedure. During this procedure, the second group of nurses who initially perform standard oral care will perform oral care using an oral care retractor. Similarly, they will complete the 'Beck Oral Assessment Guide' before the procedure and the 'Oral Care Practices Evaluation Form' after the procedure. At the end of both procedures, nurses will complete the 'Quebec Assistive Technology User Satisfaction Assessment Questionnaire (Q-ATUSA)' and the 'Interview Form'. The 'Interview Form' will be used to obtain nurses' experiences and opinions regarding oral care practices..
Study: NCT06709144

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SMA lymph node dissection
Description: The lymph node dissection boundary is on the left side of the superior mesenteric artery (SMA)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SMV lymph node dissection
Description: The lymph node dissection boundary is on the left side of the superior mesenteric vein (SMV)
Study: NCT06482814

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partial sleep deprivation (sleep restriction)
Description: During the experimental segment the sleep opportunity will be restricted to 5 hours/night. During the acclimation and recovery phases a 9-hour/night sleep opportunity will be provided.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partial sleep deprivation (sleep restriction)
Description: During the experimental segment the sleep opportunity will be restricted to 5 hours/night. During the acclimation and recovery phases a 9-hour/night sleep opportunity will be provided.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Normal sleep
Description: During the normal sleep condition a 9-hour/night sleep opportunity will be provided throughout the 10-day inpatient visit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Normal sleep
Description: During the normal sleep condition a 9-hour/night sleep opportunity will be provided throughout the 10-day inpatient visit.
Study: NCT05339126

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RNS System
Description: The RNS System provides closed loop responsive brain stimulation. The Neurostimulator monitors the electrical activity of the brain to detect abnormal activity that could lead to a seizure. If abnormal activity is detected, the neurostimulator delivers electrical stimulation to the brain through the leads to help prevent the seizure before it occurs.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RNS System
Description: The RNS System provides closed loop responsive brain stimulation. The Neurostimulator monitors the electrical activity of the brain to detect abnormal activity that could lead to a seizure. If abnormal activity is detected, the neurostimulator delivers electrical stimulation to the brain through the leads to help prevent the seizure before it occurs.
Study: NCT05467176

Intervention type: DRUG
Intervention: Relugolix
Description: Relugolix 120-mg tablet administered orally once daily following an oral loading dose of 360 mg (3 x 120-mg tablets) on Day 1
Study: NCT04967664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qutenza (capsaicin) 8% topical system
Description: High concentration capsaicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capsaicin 0.04% topical system
Description: Low-dose capsaicin control
Study: NCT05142722

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablet made to resemble active

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obicetrapib
Description: 10mg obicetrapib tablet
Study: NCT05644444

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lubricant A (sensate water-based personal lubricant) and Comparator A (non-sensate water-based lubricant)
Description: In the tolerance phase, a pea-sized lubricant will be considered a single application for oral assessment and approximately 3g of lubricant will be considered a single application for vaginal assessment.~In the treatment phase, approximately 3g of lubricant will be considered a single application.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lubricant B (sensate silicone-based personal lubricant) and Comparator B (non-sensate silicone-based personal lubricant)
Description: In the tolerance phase, a pea-sized lubricant will be considered a single application for oral assessment and approximately 3g of lubricant will be considered a single application for vaginal assessment.~In the treatment phase, approximately 3g of lubricant will be considered a single application.
Study: NCT06122415

Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma Ab42/Ab40
Description: The cut off will be predefined. The samples will be analysed prospectively every two weeks.
Study: NCT06516887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bemcentinib
Description: Bemcentinib has been investigated in a phase I/II clinical trials for solid tumors. Phase I and II clinical studies of BGB324 are ongoing in non-small cell carcinoma, in which combinations with other agents such as Phase I study of docetaxel (NCT02922777), erlotinib (NCT02424617), and pembrolizumab (NCT03184571) are also being investigated. In a phase I dose escalation study of bemcentinib in combination with docetaxel study, patients with treatment naïve, advanced lung adenocarcinoma receive docetaxel 75 mg/m2 given IV every 21 days in combination with bemcentinib. Bemcentinib dose will be escalated in a standard 3+3 fashion until a maximum tolerated dose is determined.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bemcentinib
Description: Bemcentinib has been investigated in a phase I/II clinical trials for solid tumors. Phase I and II clinical studies of BGB324 are ongoing in non-small cell carcinoma, in which combinations with other agents such as Phase I study of docetaxel (NCT02922777), erlotinib (NCT02424617), and pembrolizumab (NCT03184571) are also being investigated. In a phase I dose escalation study of bemcentinib in combination with docetaxel study, patients with treatment naïve, advanced lung adenocarcinoma receive docetaxel 75 mg/m2 given IV every 21 days in combination with bemcentinib. Bemcentinib dose will be escalated in a standard 3+3 fashion until a maximum tolerated dose is determined.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pacritinib
Description: For use in clinical studies as an oral agent, pacritinib is supplied as size #0 hard gelatin capsules with gray bodies and scarlet caps. Capsules contain 100 mg pacritinib (free base) and the following inactive ingredients: microcrystalline cellulose NF, polyethylene glycol 8000 NF, and magnesium stearate NF. The capsule gelatin is bovine derived. Pharmacies at investigational sites will receive subject-specific bottles containing 120 capsules packaged in 200 mL high-density polyethylene bottles with child-resistant closures.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pacritinib
Description: For use in clinical studies as an oral agent, pacritinib is supplied as size #0 hard gelatin capsules with gray bodies and scarlet caps. Capsules contain 100 mg pacritinib (free base) and the following inactive ingredients: microcrystalline cellulose NF, polyethylene glycol 8000 NF, and magnesium stearate NF. The capsule gelatin is bovine derived. Pharmacies at investigational sites will receive subject-specific bottles containing 120 capsules packaged in 200 mL high-density polyethylene bottles with child-resistant closures.